A New Era of Targeted Drug Discovery and the Path of Development: From Molecular

描述（由申请人提供）：我们建议将一系列课程修改为高度相关的NIDDK教育活动。{尽管对糖尿病并发症患者（如糖尿病肾病、视网膜病变和心血管疾病）的临床研究很有希望，但制药公司一直不愿在这一重要领域进行药物开发。NIDDK适时介入了几项倡议，以支持糖尿病并发症的研究和药物开发。因此，我们的最终目标将是教授研究生及以上水平的多样化目标学习者在他们的研究和相关努力中利用新的从实验到临床的经验知识，重点关注糖尿病、糖尿病并发症、肥胖、特定的、共病的和普遍的公共卫生问题。{我们将强调根据疾病期间目标变化设计治疗干预措施的重要性；例如，一些目标可能与起始更相关，其他目标可能与进展更相关，而一些目标可能与回归和再生的失败更相关。强调将研究发现转化为患者护理的方案主题将是药物发现和开发。目前为期一年的课程系列将在秋季学期回顾I-IV期试验、上市后的轨迹、安全监测、药物专利、经济刺激改革以及伦理和成本分析。在春季学期，讨论成功药物和不成功药物的分子途径和科学依据。我们的初步经验表明，这两个课程部分（以及正在进行的教学系列研讨会）有助于消除个人不能直接致力于发明药物的狭隘信念，

DESCRIPTION (provided by applicant): We propose to modify a series of courses into a highly relevant NIDDK educational activity. {Despite promising clinical studies in patients with diabetic complications, such as diabetic nephropathy, retinopathy and cardiovascular disease as examples, pharmaceutical companies have been reluctant to pursue drug development in this important area. NIDDK has duly stepped in with several initiatives to support research and drug development for diabetic complications. As such, our ultimate goal will be to teach a diverse group of targeted learners at the graduate level and beyond} to harness novel bench-to-bedside empirical knowledge in their research {and related endeavors} with a focus on diabetes, {diabetic complications}, and obesity, specific, comorbid, and pervasive public health problems. {We will highlight the importance of designing therapeutic interventions based on target changes during the disease; for example, some targets may be more relevant in initiation, others more in progression, and some more in failure of regression and regeneration.} The programmatic theme that emphasizes translation of research discoveries to patient care will be drug discovery and development. The current yearlong course series reviews Phase I-IV trials, post- marketing trajectories, safety monitoring, drug patents, and economic stimulus reform as well as ethics and cost analysis in the fall semester. In the spring semester, the molecular pathways and scientific basis of successful and unsuccessful drugs are discussed. Our preliminary experience has established that together, the two course segments (and ongoing didactic seminar series) help to disabuse the limiting belief that individuals cannot directly work towards inventing drugs, and the educational activity directs the diverse interests of this wide range of trainees towards the inspirations and rewards of translating basic science discoveries into useful patient care tools. Qualitative and quantitative reporting tools and performance tasks will evaluate the program to assure achievement of educational goals as well as future expansion of the program. Progress in achieving these objectives would mean increased NIDDK-relevant translational research skills for the diverse participants to ultimately improve patient care and public health.